KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Generalized phase I-II designs to increase long term therapeutic success rate. PMID 37038957 · Pharm Stat · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H L B
旧查询独有 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The efficacy and safety of an indocyanine green-hyaluronic acid mixture (LuminoMark™) for localization in patients with non-palpable breast lesions: A multicenter, randomized, open-label, parallel phase 3 clinical trial. PMID 37035212 · Front Oncol · 2023 The study is a randomized Phase 3 trial in oncology (breast) with a drug-containing intervention (ICG-HA mixture) for a diagnostic localization purpose, not a therapeutic intervention with a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reducing Anxiety and Dyspnea via Device-Guided Breathing (RELAX): A Multi-Site Feasibility Study in Post-Treatment Lung Cancer Survivors at Community Cancer Clinics (WF-01213). PMID 37029555 · Integr Cancer Ther · 2023 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. PMID 37025758 · Neurooncol Adv · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial. PMID 37025596 · Front Oncol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial. PMID 37018188 · PLoS One · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study. PMID 37016933 · Technol Cancer Res Treat · 2023 The record is a randomized Phase III trial in human prostate cancer with primary results, but it is ineligible because it compares two radiotherapy techniques (prostate-only vs. whole pelvic radiotherapy) and does not include a drug intervention. Furthermore, the primary outcomes are dosimetric and hematologic, with no reported time-to-event efficacy endpoint (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: A randomized controlled trial. PMID 37009103 · Front Psychiatry · 2023 The study is an oncology RCT with a drug intervention (esketamine) but does not meet the primary/key secondary time-to-event efficacy endpoint requirement. The primary outcome is the incidence of depressive symptoms (binary) at 1 month, not a survival or progression endpoint. Mortality is listed as a secondary outcome but is not described with time-to-event data. The trial phase is not specified.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
An experience with simultaneous integrated boost-volumetric-modulated arc therapy in the definitive treatment of head and neck cancer: An Indian data. PMID 37006066 · J Cancer Res Ther · 2023 The study is a randomized, prospective, human oncology trial with drug intervention and time-to-event endpoints, but the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata or abstract, making it ineligible for this specific cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC). PMID 36969063 · Front Oncol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study. PMID 36936551 · Vasc Health Risk Manag · 2023 The study is not oncologic; it addresses peripheral arterial disease. While it is a randomized trial with a drug intervention and time-to-event endpoint, it fails the fundamental oncology criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of 20% mannitol and 3% hypertonic saline for intraoperative brain relaxation during supratentorial brain tumour craniotomy in patients with a midline shift. PMID 36931929 · Neurocirugia (Engl Ed) · 2023 This is a randomized trial in oncology patients, but it is not eligible because: 1) The primary endpoint (brain relaxation score) is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any endpoint analyzed via Kaplan-Meier or HR). 2) The phase of the trial is not specified, and it is a Phase II/III or III/IIIb trial cannot be established. 3) While it involves a drug intervention (mannitol or hypertonic saline), the study focuses on a perioperative supportive care comparison, not a definitive oncology drug efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: A randomized clinical trial. PMID 36923427 · Front Oncol · 2023 The record is an original report of a randomized trial with a primary time-to-event efficacy endpoint (OS, PFS) in human oncology (hepatocellular carcinoma). However, the intervention is a surgical procedure (hepatectomy) combined with a procedural therapy (TACE). While TACE involves a drug (chemotherapy agent), the report abstract does not explicitly specify a drug-containing intervention (e.g., the type of chemotherapy agent used) as a distinct study arm; the comparison is between surgical strategies. The trial phase is not explicitly stated in the provided metadata, and cannot be inferred as Phase III/IIIb or Phase II/III. Therefore, the key criterion of a drug-containing intervention is not explicitly established, and the phase is unclear.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). PMID 36910668 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003. PMID 36896215 · Adv Radiat Oncol · 2023 This is a randomized Phase 3 trial in oncology with a drug intervention, but it reports only quality of life and toxicity outcomes, not the required primary/key secondary time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pre-transplant CRP-albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram. PMID 36875097 · Front Immunol · 2023 The record describes a retrospective prognostic nomogram study in haploidentical transplant patients. It is not a randomized controlled trial of a drug intervention; the 'randomized' tag in metadata likely refers to the random split of the cohort into training/validation sets, not a trial intervention. There is no drug-containing intervention (e.g., a novel drug vs. control). The study is a biomarker/nomogram development and validation study, not a Phase III/IIIb or Phase II/III randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognosis of the Keratinizing Squamous Cell Carcinoma of the Tongue Based on Surveillance, Epidemiology, and End Results Database. PMID 36874384 · Int J Clin Pract · 2023 The study is an observational, retrospective analysis of a public database (SEER) to create a prognostic nomogram. It is not a randomized controlled trial of a drug intervention (Phase II/III or III/IIIb). The 'Randomized Controlled Trial' publication type is a metadata error, as the randomization refers to splitting data into training/validation cohorts, not a clinical trial randomization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. PMID 36861085 · Ther Adv Med Oncol · 2023 The record describes a secondary analysis (MAIC) comparing quality-of-life outcomes from two separate trials. While the underlying trials are likely eligible, this specific report is not an original result report of a single randomized trial with a primary/key secondary efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of selenium supplementation on concurrent chemoradiotherapy in patients with cervical cancer: A randomized, double-blind, placebo-parallel controlled phase II clinical trial. PMID 36819673 · Front Nutr · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation. PMID 36817582 · Front Endocrinol (Lausanne) · 2023 The record is a population-based prognostic study and nomogram development paper, not a report of a Phase III/IIIb or Phase II/III randomized clinical trial testing a drug intervention. The 'Randomized Controlled Trial' publication type appears to be a misclassification, as the randomization described is for splitting the dataset for model training/validation, not for comparing therapeutic arms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Applying a nomogram based on preoperative CT to predict early recurrence of laryngeal squamous cell carcinoma after surgery. PMID 36806538 · J Xray Sci Technol · 2023 The study is a randomized oncology trial in humans with original results, but it lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is prediction of early recurrence using a radiomics nomogram, not a drug comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of a Video Sequence Based Intervention on Anxiety, Fatigue and Depression in Cancer Patients: Results of a Randomized Controlled Trial. PMID 36799503 · Integr Cancer Ther · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol. PMID 36798825 · Front Oncol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance. PMID 36776524 · Oncoimmunology · 2023 The record describes a preclinical and translational study with a patient prognostic analysis, not a Phase II/III randomized drug intervention trial with a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Peripheral immune factors aiding clinical parameter for better early recurrence prediction of hepatocellular carcinoma after thermal ablation. PMID 36775652 · Int J Hyperthermia · 2023 The study is an oncology analysis with a time-to-event endpoint and randomized cohorts, but it does not involve a drug-containing intervention (thermal ablation is a procedure) and does not explicitly report being a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland. PMID 36748342 · J Med Econ · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. PMID 36743520 · Ther Adv Med Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. PMID 36741254 · J Cancer · 2023 The study is an oncology RCT with a time-to-event endpoint, but it lacks a drug-containing intervention. The intervention is surgical/radiation-based, not pharmacologic.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vestibulotoxicity in Patients Undergoing Cisplatin-Based Cancer Treatment: A Phase IIIB Randomized Controlled Clinical Trial. PMID 36731442 · Audiol Neurootol · 2023 The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original report. However, the primary endpoint is the incidence of a toxicity (vestibulotoxicity), not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is excluded per protocol.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PMID 36716312 · PLoS One · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of a Sound Intervention on Physical and Emotional Well-Being in Patients with Cancer: A Prospective Randomized Trial. PMID 36657417 · Oncol Res Treat · 2023 The record describes a randomized controlled trial in oncology patients, but it is explicitly a 'pilot study' (Phase II/III-definitive status not met), the intervention is non-pharmacological (sound/music), and the primary endpoint is patient-reported improvement in quality-of-life dimensions, not a time-to-event efficacy endpoint like OS/PFS/etc.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients. PMID 36591654 · Cancer Biomark · 2023 The record describes a retrospective, bioinformatics-based prognostic modeling study using public data (TCGA). It is not a Phase II/III or Phase III randomized clinical trial evaluating a drug intervention. The 'randomized controlled trial' publication type is an error, as the randomization mentioned is only for splitting the dataset for model building, not for a clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Insights From Image Guided Radiation Therapy Credentialing for the NRG Oncology RTOG 1112 Liver Stereotactic Body Radiation Therapy Trial. PMID 36581199 · Pract Radiat Oncol · 2023 The abstract describes an analysis of the credentialing process for a trial, not the clinical efficacy results of the trial itself. Therefore, it does not meet the criteria for a primary, interim, or final result report with a time-to-event endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. PMID 36314174 · Technol Health Care · 2023 Study meets oncology, human, randomized, drug intervention, time-to-event, and original result criteria, but the trial phase (III/IIIb or II/III) is not explicitly stated in the provided metadata or abstract. Phase evidence is required for eligibility, and it cannot be inferred.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Changes of T Lymphocyte Subsets in Peripheral Blood of Patients with Intermediate and Advanced Cervical Cancer before and after Nimotuzumab Combined with Chemoradiotherapy. PMID 36265457 · Int Arch Allergy Immunol · 2023 The record describes a randomized trial in oncology with a drug intervention and time-to-event efficacy endpoints, but it fails to meet the explicit requirement for a Phase III/IIIb or Phase II/III trial. The publication type is 'Randomized Controlled Trial' but does not specify the trial phase, and the deterministic review signals 'phase3': false. Without explicit phase information, the 'phase3_or_definitive' criterion cannot be established, making the record ineligible for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of Five-Step Nutritional Interventions Conducted by a Multidisciplinary Care Team on Gastroenteric Cancer Patients Undergoing Chemotherapy: A Randomized Clinical Trial. PMID 35903847 · Nutr Cancer · 2023 Study is a randomized trial in oncology patients receiving chemotherapy, but the reported primary endpoints are nutritional status and quality of life, not a time-to-event efficacy endpoint as required for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association between vitamin D supplementation and cancer incidence and mortality: A trial sequential meta-analysis of randomized controlled trials. PMID 35352965 · Crit Rev Food Sci Nutr · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Analysis of the CONKO-001 trial: Is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer? PMID 34897105 · Int J Risk Saf Med · 2023 The record describes a critical review article analyzing the validity of the CONKO-001 trial, not an original report of trial results. It does not meet the 'original_result' criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Development and Validation of a Nomogram for Predicting Overall Survival in Pediatric Patients with Atypical Teratoid/Rhabdoid Tumors. PMID 34542900 · Turk Neurosurg · 2023 The study is an oncology, human, original report with a time-to-event endpoint (OS). However, it is a retrospective, population-based cohort study using a public database (SEER), not a Phase III/IIIb or Phase II/III randomized trial. The abstract describes a prognostic nomogram development/validation study; it is not a clinical trial. The 'Randomized Controlled Trial' publication type is a metadata error. The study includes 'chemotherapy' as a variable but does not describe a randomized drug intervention as the primary comparison. Therefore, it does not meet the core eligibility criteria of being a definitive-phase randomized trial with a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatment-a randomized controlled multicenter trial. PMID 36180944 · Trials · 2022-Sep-30 The record is a protocol for a randomized trial in oncology (human, randomized, time-to-event endpoint) but lacks explicit Phase III/IIIb or Phase II/III designation, does not present formal results, and the intervention is not drug-containing.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial. PMID 36180115 · BMJ Open · 2022-Sep-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer-Hyperthermia versus Normothermia: A Randomized Controlled Trial. PMID 36233653 · J Clin Med · 2022-Sep-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of anesthesia on the outcome of high-grade glioma patients undergoing supratentorial resection: study protocol for a pragmatic randomized controlled trial. PMID 36167574 · Trials · 2022-Sep-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. PMID 35439293 · Blood Adv · 2022-Sep-27 The record describes a retrospective, adjusted comparison of a non-randomized cohort (R-B) to an arm of an external randomized trial (MCL Younger). It is not the original result report of a Phase III randomized trial. The publication is tagged as a 'Randomized Controlled Trial', but the study design analyzed is not a standalone randomized trial. Phase information for the study being conducted is not explicitly stated as Phase III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Does Multi-Strain Probiotic Supplementation Impact the Effort Capacity of Competitive Road Cyclists? PMID 36231510 · Int J Environ Res Public Health · 2022-Sep-26 Not an oncology study. The record is a randomized trial of a probiotic supplement in athletes, assessing exercise capacity, not a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial. No drug-containing intervention for cancer is present. No primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial. PMID 36167367 · BMJ Open · 2022-Sep-26 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Improve the cervical cancer prevention behaviors through mobile-based educational intervention based on I-CHANGE model: study protocol for a randomized controlled trial. PMID 36153560 · Trials · 2022-Sep-24 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial. PMID 36153496 · BMC Cancer · 2022-Sep-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. PMID 36108657 · Lancet · 2022-Sep-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection. PMID 36197272 · Medicine (Baltimore) · 2022-Sep-23 The study is a randomized, human oncology trial with a drug intervention, but it lacks a clear Phase III/IIIb or Phase II/III designation and does not report a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -